Fidelity Investments’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $152M | Buy |
7,559,901
+950,372
| +14% | +$19.1M | 0.01% | 937 |
|
|
2025
Q1 | $130M | Buy |
6,609,529
+113,658
| +2% | +$2.24M | 0.01% | 982 |
|
|
2024
Q4 | $146M | Buy |
6,495,871
+199,692
| +3% | +$4.49M | 0.01% | 954 |
|
|
2024
Q3 | $161M | Buy |
6,296,179
+601,611
| +11% | +$15.4M | 0.01% | 906 |
|
|
2024
Q2 | $133M | Sell |
5,694,568
-551,725
| -9% | -$12.9M | 0.01% | 934 |
|
|
2024
Q1 | $110M | Buy |
6,246,293
+1,085,051
| +21% | +$19.1M | 0.01% | 1017 |
|
|
2023
Q4 | $71.4M | Buy |
5,161,242
+1,485,029
| +40% | +$20.6M | 0.01% | 1150 |
|
|
2023
Q3 | $50.2M | Sell |
3,676,213
-325,398
| -8% | -$4.44M | ﹤0.01% | 1239 |
|
|
2023
Q2 | $81.7M | Buy |
4,001,611
+838,129
| +26% | +$17.1M | 0.01% | 1081 |
|
|
2023
Q1 | $69.3M | Buy |
3,163,482
+3,139,646
| +13,172% | +$68.8M | 0.01% | 1119 |
|
|
2022
Q4 | $390K | Buy |
+23,836
| New | +$390K | ﹤0.01% | 2799 |
|
|
2022
Q2 | – | Sell |
-92,540
| Closed | -$696K | – | 5040 |
|
|
2022
Q1 | $696K | Sell |
92,540
-409,999
| -82% | -$3.08M | ﹤0.01% | 2880 |
|
|
2021
Q4 | $4.52M | Sell |
502,539
-75,134
| -13% | -$676K | ﹤0.01% | 2392 |
|
|
2021
Q3 | $9.43M | Sell |
577,673
-83,810
| -13% | -$1.37M | ﹤0.01% | 2152 |
|
|
2021
Q2 | $20.9M | Buy |
661,483
+99,847
| +18% | +$3.16M | ﹤0.01% | 1835 |
|
|
2021
Q1 | $19M | Sell |
561,636
-91,143
| -14% | -$3.08M | ﹤0.01% | 1827 |
|
|
2020
Q4 | $57.6M | Buy |
652,779
+33,653
| +5% | +$2.97M | 0.01% | 1268 |
|
|
2020
Q3 | $50.4M | Buy |
619,126
+205,280
| +50% | +$16.7M | 0.01% | 1188 |
|
|
2020
Q2 | $45.7M | Buy |
413,846
+146,221
| +55% | +$16.2M | 0.01% | 1203 |
|
|
2020
Q1 | $17.2M | Buy |
+267,625
| New | +$17.2M | ﹤0.01% | 1465 |
|